TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback